Bioxytran Finalizes ProLectin-M Antiviral Dose Optimization

In a significant development, BIOXYTRAN, INC., a biotechnology company situated in Boston, Massachusetts, has concluded the dose optimization phase of its experimental antiviral medication, ProLectin-M. This advancement comes from a randomized, double-blind, placebo-controlled study, with forthcoming preliminary results. Complete data will soon be submitted to the FDA, as part of Bioxytran’s ongoing Investigational New Drug clinical trials for ProLectin-M.

The trial was structured to evaluate several doses of ProLectin-M against a placebo over a span of five days. The primary goal set for the study was to achieve an undetectable viral load by the seventh day. In addition to this, the trial focused on secondary objectives, such as early viral clearance by the third and fifth days, improvement in symptoms as gauged by the WHO Clinical Progression Scale, and a thorough assessment of the drug's safety and tolerability.

The success of this trial has significant strategic implications. The data collected will be instrumental in designing further trials aimed at treating viral infections like COVID-19, Influenza, RSV, and EBV. This study also supports submissions to the FDA and the Central Drugs Standard Control Organization, following the agencies’ guidelines. Previous trials have shown promising results, with a 100% responder rate, indicated by negative PCR results by the seventh day, and an 88% responder rate by the third day.

Dr. Leslie Ajayi, Bioxytran's Chief Medical Officer, highlighted the trial as a pivotal step towards positioning ProLectin-M as a primary antiviral treatment. The consistency in trial outcomes, including complete viral clearance observed in earlier studies, bolsters their confidence for upcoming clinical trials. The next phases involve thorough data analysis and subsequent submissions to FDA and CDSCO as groundwork for future critical trials.

Bioxytran’s CEO, David Platt, emphasized that optimizing the dose is a crucial milestone for their broad-spectrum antiviral platform, asserting that the trial results will enable strategic progress for ProLectin-M.

ProLectin-M is described as a therapeutic complex carbohydrate that intervenes in viral entry mechanisms, with potential applications in treating upper respiratory viral infections and bolstering pandemic readiness.

Bioxytran, Inc. focuses on developing groundbreaking treatments across three primary domains: virology, oncology (specifically metastasis inhibition), and oxygen transport, which could potentially aid in reducing delays in stroke therapy by over 90%. Their pipeline includes BXT-25, a novel stroke treatment aiming to significantly cut down treatment time.